Search Result

Results for "

lymphocytic leukemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Adenosine Deaminase (1) Aminopeptidase (1) Antibiotic (3) Apoptosis (8) Bacterial (1) Btk (6) Calcium Channel (1) Casein Kinase (4) CXCR (3) DNA Alkylator/Crosslinker (4) DNA/RNA Synthesis (2) Drug Metabolite (2) FLT3 (2) Fungal (1) Glutathione S-transferase (1) IFNAR (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (3) Ligands for Target Protein for PROTAC (1) MAP4K (1) Necroptosis (1) NF-κB (2) NO Synthase (1) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (2) Phosphatase (2) PI3K (4) PKA (1) PROTACs (1) SF3B1 (1) Syk (2)
By Research Areas:	Cancer (36) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (6) Neurological Disease (1)

By Targets:

ADC Cytotoxin (1)

Adenosine Deaminase (1)

Aminopeptidase (1)

Antibiotic (3)

Apoptosis (8)

Bacterial (1)

Btk (6)

Calcium Channel (1)

Casein Kinase (4)

CXCR (3)

DNA Alkylator/Crosslinker (4)

DNA/RNA Synthesis (2)

Drug Metabolite (2)

FLT3 (2)

Fungal (1)

Glutathione S-transferase (1)

IFNAR (1)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (3)

Ligands for Target Protein for PROTAC (1)

MAP4K (1)

Necroptosis (1)

NF-κB (2)

NO Synthase (1)

Nuclear Factor of activated T Cells (NFAT) (1)

Nucleoside Antimetabolite/Analog (2)

Phosphatase (2)

PI3K (4)

PKA (1)

PROTACs (1)

SF3B1 (1)

Syk (2)

By Research Areas:

Cancer (36)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (6)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126030

(+)-Syringaresinol	Nuclear Factor of activated T Cells (NFAT)	Cancer
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC₅₀ of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia .

HY-W757743

Acalabrutinib-d3 ACP-196-d₃	Isotope-Labeled Compounds	Others
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-P99442

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .

HY-N9210

1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid	Others	Cancer
1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid, a ellagic acid derivative of Agrostistachys hookeri, exhibits activity against cultured P-388 lymphocytic leukemia cells .

HY-151211

BTK-IN-16	Btk	Inflammation/Immunology Cancer
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC₅₀s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .

HY-N1649

2,3,2'',3''-Tetrahydroochnaflavone	Others	Cancer
2,3,2'',3''-Tetrahydroochnaflavone is a biflavonoid, which can be isolated from the leaves of Quintinia acutifolia. 2,3,2'',3''-Tetrahydroochnaflavone shows some cytotoxicity against P388 murine lymphocytic leukemia cells, with an IC₅₀ of 8.2 µg/mL .

HY-123794

MP07-66	Phosphatase	Cancer
MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation .

HY-114989

Fluorizoline 1 Publications Verification	Apoptosis	Cancer
Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner .

HY-12279

Umbralisib 3 Publications Verification TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach .

HY-12279B

Umbralisib sulfate TGR-1202 sulfate; RP-5264 sulfate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach .

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-12279C

Umbralisib hydrochloride 3 Publications Verification TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach .

HY-12279A

Umbralisib tosylate TGR-1202 tosylate; RP5264 tosylate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach .

HY-111134

TAN 420C

Antibiotic Infection Cancer

TAN 420C is an antibiotic that shows a strong cytotoxic activity against the lymphocytic leukemia .

TAN 420C	Antibiotic	Infection Cancer
TAN 420C is an antibiotic that shows a strong cytotoxic activity against the lymphocytic leukemia .

HY-17600

Acalabrutinib Maximum Cited Publications 20 Publications Verification ACP-196	Btk	Cancer
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL) . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-108603

Bryostatin 2 (+)-Bryostatin 2	Others	Cancer
Bryostatin 2 ((+)-Bryostatin 2) is a 20-membered ring lactone that can be found in Bryozoan Eugufa neritina L. Bryostatin 2 has the potential for the research of P-388 lymphocytic leukemia .

HY-122562

MT-802 1 Publications Verification	PROTACs Btk	Inflammation/Immunology Cancer
MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC₅₀ of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL) .

HY-160041A

Olaptesed pegol sodium	CXCR	Cancer
Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment .

HY-13593

Chlorambucil 4 Publications Verification CB-1348; WR-139013	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .

HY-160041

Olaptesed pegol	CXCR	Cancer
Olaptesed pegol (NOX-A12) L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment .

HY-13593S

Chlorambucil-d8 CB-1348-d₈; WR-139013-d₈	Isotope-Labeled Compounds DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈ is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-13593S1

Chlorambucil-d8-1 CB-1348-d₈-1; WR-139013-d₈-1	Isotope-Labeled Compounds DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-121123

Adamantanine 2-Aminoadamantane-2-carboxylic acid	Aminopeptidase	Cancer
Adamantanine (2-Aminoadamantane-2-carboxylic acid) inhibits the transport of methionine (K_i is 0.76 mM) and leucine into Ehrlich ascites carcinoma cells. Adamantanine inhibits proliferation of P388 lymphocytic leukemia cells with an IC₅₀ of >1 mM. Adamantanine inhibits the leucine aminopeptidase with an I/S_0.5 of 10.5 .

HY-12908

Bcl-xL antagonist 2
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-X_L with an IC₅₀ and K_i of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .

HY-150885

BTK ligand 1	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .

HY-16466

Spliceostatin A	SF3B1	Cancer
Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells .

HY-100867A

TAK-659 hydrochloride	Syk FLT3	Cancer
TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .

HY-100867

TAK-659	Syk FLT3	Cancer
TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .

HY-129390

Orelabrutinib ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

HY-136268

AQX-435	Phosphatase Apoptosis	Inflammation/Immunology
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth .

HY-N6727

Gliotoxin Aspergillin	Apoptosis PKA NF-κB Bacterial Fungal Antibiotic	Infection Inflammation/Immunology Cancer
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .

HY-B1640

Ethacrynic acid 2 Publications Verification Etacrynic acid	Glutathione S-transferase NF-κB Calcium Channel NO Synthase	Inflammation/Immunology Cancer
Ethacrynic acid has anti-inflammatory and anticancer activity. Ethacrynic acid is an orally active diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferase (GSTs) and Wnt signaling pathways. Ethacrynic acid is a radiosensitizer. Ethacrynic acid can inhibit airway smooth muscle (ASM) contraction in mice. Ethacrynic acid can increase the outflow of aqueous humor from the eye for the study of glaucoma .

HY-N3065

Pierreione B	Others	Cancer
Pierreione B is a pyranoisoflavone, that can be isolated from the leaves and twigs of Antheroporum pierrei. Pierreione B demonstrates solid tumor selectivity with minimal cytotoxicity .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-12456

Duocarmycin SA	Antibiotic ADC Cytotoxin DNA Alkylator/Crosslinker Necroptosis Apoptosis	Cancer
Duocarmycin SA is an orally active antitumor antibiotic with an IC₅₀ of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .

HY-14951

Firategrast 5+ Cited Publications SB 683699	Integrin	Neurological Disease
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .

HY-136650

Fludarabine triphosphate F-ara-ATP	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP), the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis .

HY-136650A

Fludarabine triphosphate trisodium F-ara-ATP trisodium	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis .

HY-13599

Cladribine 3 Publications Verification 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA	Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .

HY-17600S

Acalabrutinib-d4 ACP-196-d₄	Btk	Cancer
Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor[1]. Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Samalizumab ALXN 6000	Inhibitory Antibodies	Cancer
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .

Cat. No.	Product Name	Category	Target	Chemical Structure